Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$73.0 million.

  • Nurix Therapeutics' Free Cash Flow fell 4346.98% to -$73.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$263.5 million, marking a year-over-year decrease of 4487.59%. This contributed to the annual value of -$263.5 million for FY2025, which is 4487.59% down from last year.
  • Nurix Therapeutics' Free Cash Flow amounted to -$73.0 million in Q4 2025, which was down 4346.98% from -$60.1 million recorded in Q3 2025.
  • Nurix Therapeutics' Free Cash Flow's 5-year high stood at $24.1 million during Q4 2023, with a 5-year trough of -$73.0 million in Q4 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$44.1 million (2023), whereas its average is -$39.9 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 73941.75% in 2022, then soared by 15948.67% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Free Cash Flow stood at -$31.8 million in 2021, then dropped by 27.53% to -$40.5 million in 2022, then skyrocketed by 159.49% to $24.1 million in 2023, then crashed by 310.99% to -$50.9 million in 2024, then crashed by 43.47% to -$73.0 million in 2025.
  • Its Free Cash Flow stands at -$73.0 million for Q4 2025, versus -$60.1 million for Q3 2025 and -$65.8 million for Q2 2025.